- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Determining Appropriate Duration of Treatment
Immunotherapeutic agents have demonstrated effectiveness at delivering sustained treatment responses; however, these agents are associated with substantial costs. Furthermore, prolonged use of immunotherapy can increase the likelihood that a patient will experience treatment toxicities.
Richard W. Joseph, MD, explains how clinical studies designed to assess appropriate duration of immunotherapy treatment can help reduce these patient burdens.
Dr Joseph notes that clinical trials of immunotherapy in different types of cancer have demonstrated durable response rates. Keeping patients on immunotherapy for a long period of time may not always be necessary, and studies that evaluate the appropriate duration of treatment with immunotherapeutic agents are needed. If cancer recurs, he adds, patients may still respond when immunotherapy is restarted.
By appropriately limiting the length of treatment with immunotherapy based on data from clinical trials, healthcare professionals can reduce the cost burden and the likelihood of experiencing treatment toxicities, Dr Joseph remarks.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
